9,750 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 9,750 shares of the medical device company's stock, valued at approximately $654,000.

A number of other hedge funds have also recently bought and sold shares of DXCM. Vanguard Group Inc. raised its stake in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company's stock valued at $6,186,539,000 after purchasing an additional 136,282 shares in the last quarter. Legal & General Group Plc lifted its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after buying an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. 1832 Asset Management L.P. raised its position in shares of DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company's stock valued at $252,906,000 after acquiring an additional 20,400 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in DexCom by 14.4% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company's stock worth $183,336,000 after purchasing an additional 203,043 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DXCM shares. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Robert W. Baird lifted their target price on DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, August 5th. BTIG Research dropped their price target on DexCom from $156.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, July 26th. Finally, Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $104.59.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

DexCom Price Performance

Shares of DXCM stock traded up $1.20 during midday trading on Friday, reaching $75.88. 6,879,181 shares of the company were exchanged, compared to its average volume of 3,934,491. The company's 50 day moving average price is $70.03 and its two-hundred day moving average price is $91.67. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market cap of $29.64 billion, a P/E ratio of 45.44, a PEG ratio of 2.22 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.